The prevalence of alpha-1 antitrypsin deficiency among patients found to have airflow obstruction

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 9, Issue 4, 2012, Pages 352-358

  Rahaghi, Franck F ^a   Sandhaus, Robert A ^b   Strange, Charlie ^c   Hogarth, Douglas Kyle ^d   Eden, Edward ^e   Stocks, James M ^f   Krowka, Michael J ^g   Stoller, James K ^h  

^a DEPARTMENT OF COLORECTAL SURGERY   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^f UNIVERSITY OF TEXAS AT TYLER   (United States)

^g MAYO CLINIC   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Alpha 1 Antitrypsin Deficiency; Chronic Obstructive Pulmonary Disease; Pulmonary Function Test; Respiratory Care; Spirometry

Indexed keywords

ALPHA 1 ANTITRYPSIN; BRONCHODILATING AGENT;

ADULT; AFRICAN AMERICAN; AIRWAY OBSTRUCTION; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; DISEASE CARRIER; FEASIBILITY STUDY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENOTYPE; HETEROZYGOTE; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; TOTAL LUNG CAPACITY; UNITED STATES;

AGED; ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; FEASIBILITY STUDIES; FEMALE; GENETIC MARKERS; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MEDICAL LABORATORY PERSONNEL; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; RESPIRATORY THERAPY DEPARTMENT, HOSPITAL;

EID: 84865194902     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2012.669433     Document Type: Article

References (34)

1. de Serres FJ. Worldwide racial and ethnic distribution of alpha1- antitrypsin defi ciency: summary of an analysis of published genetic epidemiologic surveys. Chest 2002 Nov; 122(5):1818-29.
2. Silverman EK, Sandhaus RA. Clinical practice. Alpha1- antitrypsin defi ciency. N.Engl.J.Med. 2009 Jun 25; 360(26):2749-57.
3. Luisetti M, Seersholm N. Alpha1-antitrypsin defi ciency. 1: epidemiology of alpha1-antitrypsin defi ciency. Th orax 2004 Feb; 59(2):164-9.
4. Lieberman J, Winter B, Sastre A. Alpha 1-antitrypsin Pi-types in 965 COPD patients. Chest 1986 Mar; 89(3):370-3.
5. Campbell EJ. Alpha1-antitrypsin defi ciency: incidence and detection program. Respir Med 2000 Aug; 94 Suppl C:S18-S21.
6. American Th oracic Society/European Respiratory Society. Statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin defi ciency. Am J Respir Crit Care Med 2003 Oct 1; 168(7):818-900.
7. Campos MA, Wanner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with alpha1- antitrypsin defi ciency between 1968 and 2003. Chest 2005 Sep; 128(3):1179-86.
8. Stoller JK, Sandhaus RA, Turino G, Dickson R, Rodgers K, Strange C. Delay in diagnosis of alpha1-antitrypsin defi ciency: a continuing problem. Chest 2005 Oct; 128(4):1989-94.
9. Stoller JK, Aboussouan LS. Alpha1-antitrypsin defi ciency. Lancet 2005 Jun 25; 365(9478):2225-36.
10. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR. Why dont physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999 Oct 20; 282(15):1458-65.
11. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al. Standardisation of spirometry. Eur Respir J 2005 Aug; 26(2):319-38.
12. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999 Jan; 159(1):179-87.
13. Strange C, Dickson R, Carter C, Carpenter MJ, Holladay B, Lundquist R, Brantly ML. Genetic testing for alpha1- antitrypsin defi ciency. Genet Med 2004 Jul; 6(4):204-10.
14. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van WC, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007 Sep 15; 176(6):532-55.
15. Fleiss JL, Levin BA, Paik MC. Statistical Methods for Rates and Proportions. 3rd ed. Hoboken, NJ: Wiley; 2003.
16. Newcombe RG. Two-sided confi dence intervals for the single proportion: comparison of seven methods. Stat Med 1998 Apr 30; 17(8):857-72.
17. Clopper CJ, Person ES. Th e use of confi dence or fi ducial limits illustrated in the case binomial. Biometrika 1934; 26:404-13.
18. Wencker M, Marx A, Konietzko N, Schaefer B, Campbell EJ. Screening for alpha1-Pi defi ciency in patients with lung diseases. Eur Respir J 2002 Aug; 20(2):319-24.
19. Bals R, Koczulla R, Kotke V, Andress J, Blackert K, Vogelmeier C. Identifi cation of individuals with alpha-1-antitrypsin defi ciency by a targeted screening program. Respir Med 2007 Aug; 101(8):1708-14.
20. de la Roza C, Rodriguez-Frias F, Lara B, Vidal R, Jardi R, Miravitlles M. Results of a case-detection programme for alpha1-antitrypsin defi ciency in COPD patients. Eur Respir J 2005 Oct;26(4):616-22.
21. Corda L, Bertella E, Pini L, Pezzini A, Medicina D, Boni E, Guerini M, Trivella S, Grassi V, Tantucci C. Diagnostic fl ow chart for targeted detection of alpha1-antitrypsin defi ciency. Respir Med 2006 Mar; 100(3):463-70.
22. Brantly ML, Mishra VS, Viranovskaya N, Zienko L, Corcoran V, Leonard S, Adams H, Lundquist R, Pollock D. Statewide targeted screening and detection of AAT defi ciency. Am J Respir Crit Care Med 2003: 167
23. Crit Care Med 2003:167; A222.
24. Luisetti M, Massi G, Massobrio M, Guarraci P, Menchicchi FM, Beccaria M, Balbi B. A national program for detection of alpha 1-antitrypsin defi ciency in Italy. Gruppo I.D.A. Respir Med 1999 Mar; 93(3):169-72.
25. Ferrarotti I, Gorrini M, Scabini R, Ottaviani S, Mazzola P, Campo I, Zorzetto M, Luisetti M. Secondary outputs of alpha1-antitrypsin defi ciency targeted detection programme. Respir Med 2008 Mar; 102(3):354-8.
26. Matzen RN, Bader PI, Block WD. Alpha1-Antitrypsin defi ciency in clinic patients. Ann Clin Res 1977 Apr; 9(2):88-92.
27. Rahaghi F, Ortega I, Rahaghi N, Oliveira E, Ramirez J, Smolley L, Stoller JK. Physician alert suggesting alpha-1 antitrypsin defi ciency testing in pulmonary function test (PFT) results. COPD 2009 Feb; 6(1):26-30.
28. Aboussouan LS, Stoller JK. Detection of alpha-1 antitrypsin defi ciency: A review. Respir Med 2009 Mar; 103(3):335-41.
29. Miller MR, Quanjer PH, Swanney MP, Ruppel G, Enright PL. Interpreting lung function data using 80% predicted and fi xed thresholds misclassifi es more than 20% of patients. Chest 2011 Jan; 139(1):52-9.
30. Joo MJ, Au DH, Fitzgibbon ML, McKell J, Lee TA. Determinants of spirometry use and accuracy of COPD diagnosis in primary care. J Gen Intern Med 2011 Nov; 26(11):1272-7.
31. Joo MJ, Lee TA, Weiss KB. Geographic variation of spirometry use in newly diagnosed COPD. Chest 2008 Jul; 134(1):38-45.
32. Han MK, Kim MG, Mardon R, Renner P, Sullivan S, Diette GB, Martinez FJ. Spirometry utilization for COPD: how do we measure up? Chest 2007 Aug; 132(2):403-9.
33. Boland BJ, Wollan PC, Silverstein MD. Yield of laboratory tests for case-fi nding in the ambulatory general medical examination. Am J Med 1996 Aug; 101(2):142-52.
34. Ferrarotti I, Gorrini M, Scabini R, Ottaviani S, Mazzola P, Campo I, Zorzetto M, Luisetti M. Secondary outputs of alpha1-antitrypsin defi ciency targeted detection programme. Respir Med 2008 Mar; 102(3):354-8.